Lastly, we reveal that depleting perlecan in the stroma combined with chemotherapy prolongs mouse survival, supporting it as a potential target for anti-stromal therapies in pancreatic cancer. This evidence concerns the gene HSPG2 and familial pancreatic carcinoma.